Will it Cut Deaths in Half? –

February 10, 2018 – Purdue eventually acknowledged that its promotions exaggerated the drug’s safety and minimized the risks of addiction. After federal investigations, the company and three executives pleaded guilty in 2007 and agreed to pay more than $600 million for misleading the public about the risks of OxyContin. But the drug continued to rack up blockbuster sales. Dr. Andrew Kolodny, director of opioid policy research at Brandeis University and an advocate for stronger regulation of opioid drug companies, said Purdue’s decision is helpful, but that to make a real difference, other opioid drug companies have to do the same.
Full Story @ ChicagoTribune.com

SIGN UP TODAY!

Subscribe Today! Your best source of current news, information and opinion about the issues that matter to you most. Serving the treatment industry, recovery community and health and wellness professionals.